Roivant Sciences Stock Performance
| ROIV Stock | USD 11.38 0.01 0.09% |
Roivant Sciences has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 0.94, which implies possible diversification benefits within a given portfolio. Roivant Sciences returns are very sensitive to returns on the market. As the market goes up or down, Roivant Sciences is expected to follow. Roivant Sciences right now holds a risk of 1.9%. Please check Roivant Sciences maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Roivant Sciences will be following its historical price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Roivant Sciences are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable forward indicators, Roivant Sciences is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return (0.09) | Five Day Return (2.74) | Year To Date Return (5.79) | Ten Year Return 9.42 | All Time Return 9.42 |
1 | Disposition of 1653 shares by Richard Pulik of Roivant Sciences at 11.19 subject to Rule 16b-3 | 04/28/2025 |
2 | Disposition of 273959 shares by Vivek Ramaswamy of Roivant Sciences at 11.47 subject to Rule 16b-3 | 05/06/2025 |
3 | Disposition of 625000 shares by Vivek Ramaswamy of Roivant Sciences at 11.18 subject to Rule 16b-3 | 05/07/2025 |
4 | Disposition of 10945 shares by Matthew Gline of Roivant Sciences at 11.04 subject to Rule 16b-3 | 05/20/2025 |
5 | Disposition of 433722 shares by Venker Eric of Roivant Sciences at 11.07 subject to Rule 16b-3 | 06/02/2025 |
6 | Disposition of 566278 shares by Venker Eric of Roivant Sciences at 11.22 subject to Rule 16b-3 | 06/03/2025 |
7 | Disposition of 547430 shares by Vivek Ramaswamy of Roivant Sciences at 11.34 subject to Rule 16b-3 | 06/04/2025 |
8 | Acquisition by Venker Eric of 250000 shares of Roivant Sciences at 3.85 subject to Rule 16b-3 | 06/06/2025 |
9 | Disposition of 10945 shares by Matthew Gline of Roivant Sciences at 10.97 subject to Rule 16b-3 | 06/11/2025 |
10 | Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled ... | 06/16/2025 |
11 | Disposition of 565266 shares by Vivek Ramaswamy of Roivant Sciences at 11.45 subject to Rule 16b-3 | 06/18/2025 |
12 | Disposition of 577007 shares by Vivek Ramaswamy of Roivant Sciences at 11.46 subject to Rule 16b-3 | 06/20/2025 |
13 | Peering Into Roivant Sciencess Recent Short Interest | 06/25/2025 |
14 | Disposition of 1170646 shares by Gold Daniel Allen of Roivant Sciences subject to Rule 16b-3 | 06/27/2025 |
15 | Should Invesco SP MidCap 400 GARP ETF Be on Your Investing Radar | 07/11/2025 |
16 | Acquisition by Epperly Melissa B, of 1609 shares of Roivant Sciences subject to Rule 16b-3 | 07/17/2025 |
17 | Disposition of 100000 shares by Venker Eric of Roivant Sciences at 11.52 subject to Rule 16b-3 | 07/21/2025 |
18 | What Does the Market Think About Roivant Sciences | 07/23/2025 |
| Begin Period Cash Flow | 6.6 B | |
| Total Cashflows From Investing Activities | -1.8 B |
Roivant Sciences Relative Risk vs. Return Landscape
If you would invest 1,119 in Roivant Sciences on April 26, 2025 and sell it today you would earn a total of 19.00 from holding Roivant Sciences or generate 1.7% return on investment over 90 days. Roivant Sciences is currently generating 0.0452% in daily expected returns and assumes 1.899% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Roivant, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Roivant Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Roivant Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Roivant Sciences, and traders can use it to determine the average amount a Roivant Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0238
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ROIV |
Estimated Market Risk
| 1.9 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.05 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Roivant Sciences is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Roivant Sciences by adding it to a well-diversified portfolio.
Roivant Sciences Fundamentals Growth
Roivant Stock prices reflect investors' perceptions of the future prospects and financial health of Roivant Sciences, and Roivant Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Roivant Stock performance.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.11 | ||||
| Operating Margin | (48.24) % | ||||
| Current Valuation | 2.96 B | ||||
| Shares Outstanding | 679.81 M | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 266.51 X | ||||
| Revenue | 29.05 M | ||||
| Gross Profit | (516.47 M) | ||||
| EBITDA | (1.1 B) | ||||
| Net Income | (356.73 M) | ||||
| Cash And Equivalents | 1.94 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 100.17 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 6.20 X | ||||
| Book Value Per Share | 6.74 X | ||||
| Cash Flow From Operations | (839.45 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Market Capitalization | 7.74 B | ||||
| Total Asset | 5.44 B | ||||
| Retained Earnings | 116.06 M | ||||
| Working Capital | 4.85 B | ||||
About Roivant Sciences Performance
Evaluating Roivant Sciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Roivant Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Roivant Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 414.10 | 214.75 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.19) | (0.20) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about Roivant Sciences performance evaluation
Checking the ongoing alerts about Roivant Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Roivant Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 29.05 M. Net Loss for the year was (356.73 M) with loss before overhead, payroll, taxes, and interest of (516.47 M). | |
| Roivant Sciences currently holds about 1.94 B in cash with (839.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: What Does the Market Think About Roivant Sciences |
- Analyzing Roivant Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Roivant Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Roivant Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Roivant Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Roivant Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Roivant Sciences' stock. These opinions can provide insight into Roivant Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.